1560 related articles for article (PubMed ID: 16437455)
21. Second-generation antipsychotics for major depressive disorder and dysthymia.
Komossa K; Depping AM; Gaudchau A; Kissling W; Leucht S
Cochrane Database Syst Rev; 2010 Dec; (12):CD008121. PubMed ID: 21154393
[TBL] [Abstract][Full Text] [Related]
22. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.
Schneider LS; Tariot PN; Dagerman KS; Davis SM; Hsiao JK; Ismail MS; Lebowitz BD; Lyketsos CG; Ryan JM; Stroup TS; Sultzer DL; Weintraub D; Lieberman JA;
N Engl J Med; 2006 Oct; 355(15):1525-38. PubMed ID: 17035647
[TBL] [Abstract][Full Text] [Related]
23. Aripiprazole versus other atypical antipsychotics for schizophrenia.
Komossa K; Rummel-Kluge C; Schmid F; Hunger H; Schwarz S; El-Sayeh HG; Kissling W; Leucht S
Cochrane Database Syst Rev; 2009 Oct; (4):CD006569. PubMed ID: 19821375
[TBL] [Abstract][Full Text] [Related]
24. Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuse.
Temmingh HS; Williams T; Siegfried N; Stein DJ
Cochrane Database Syst Rev; 2018 Jan; 1(1):CD011057. PubMed ID: 29355909
[TBL] [Abstract][Full Text] [Related]
25. Aripiprazole versus other atypical antipsychotics for schizophrenia.
Khanna P; Suo T; Komossa K; Ma H; Rummel-Kluge C; El-Sayeh HG; Leucht S; Xia J
Cochrane Database Syst Rev; 2014 Jan; 2014(1):CD006569. PubMed ID: 24385408
[TBL] [Abstract][Full Text] [Related]
26. Amisulpride versus other atypical antipsychotics for schizophrenia.
Komossa K; Rummel-Kluge C; Hunger H; Schmid F; Schwarz S; Silveira da Mota Neto JI; Kissling W; Leucht S
Cochrane Database Syst Rev; 2010 Jan; (1):CD006624. PubMed ID: 20091599
[TBL] [Abstract][Full Text] [Related]
27. Atypical antipsychotics for the treatment of dementia-related behaviors: an update.
Daiello LA
Med Health R I; 2007 Jun; 90(6):191-4. PubMed ID: 17633594
[TBL] [Abstract][Full Text] [Related]
28. Atypical antipsychotics for disruptive behaviour disorders in children and youths.
Loy JH; Merry SN; Hetrick SE; Stasiak K
Cochrane Database Syst Rev; 2012 Sep; (9):CD008559. PubMed ID: 22972123
[TBL] [Abstract][Full Text] [Related]
29. Summary of the comparative effectiveness review on off-label use of atypical antipsychotics.
Maher AR; Theodore G
J Manag Care Pharm; 2012 Jun; 18(5 Suppl B):S1-20. PubMed ID: 22784311
[TBL] [Abstract][Full Text] [Related]
30. Comparative Outcomes of Commonly Used Off-Label Atypical Antipsychotics in the Treatment of Dementia-Related Psychosis: A Network Meta-analysis.
Yunusa I; Rashid N; Demos GN; Mahadik BS; Abler VC; Rajagopalan K
Adv Ther; 2022 May; 39(5):1993-2008. PubMed ID: 35247186
[TBL] [Abstract][Full Text] [Related]
31. Comparison of longer-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: a trial using equipoise-stratified randomization.
Jin H; Shih PA; Golshan S; Mudaliar S; Henry R; Glorioso DK; Arndt S; Kraemer HC; Jeste DV
J Clin Psychiatry; 2013 Jan; 74(1):10-8. PubMed ID: 23218100
[TBL] [Abstract][Full Text] [Related]
32. Haloperidol alone or in combination for acute mania.
Cipriani A; Rendell JM; Geddes JR
Cochrane Database Syst Rev; 2006 Jul; (3):CD004362. PubMed ID: 16856043
[TBL] [Abstract][Full Text] [Related]
33. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis.
Rummel-Kluge C; Komossa K; Schwarz S; Hunger H; Schmid F; Lobos CA; Kissling W; Davis JM; Leucht S
Schizophr Res; 2010 Nov; 123(2-3):225-33. PubMed ID: 20692814
[TBL] [Abstract][Full Text] [Related]
34. Aripiprazole (intramuscular) for psychosis-induced aggression or agitation (rapid tranquillisation).
Ostinelli EG; Jajawi S; Spyridi S; Sayal K; Jayaram MB
Cochrane Database Syst Rev; 2018 Jan; 1(1):CD008074. PubMed ID: 29308601
[TBL] [Abstract][Full Text] [Related]
35. Antidepressants for agitation and psychosis in dementia.
Seitz DP; Adunuri N; Gill SS; Gruneir A; Herrmann N; Rochon P
Cochrane Database Syst Rev; 2011 Feb; (2):CD008191. PubMed ID: 21328305
[TBL] [Abstract][Full Text] [Related]
36. Healthcare costs associated with treatment of bipolar disorder using a mood stabilizer plus adjunctive aripiprazole, quetiapine, risperidone, olanzapine or ziprasidone.
Jing Y; Kim E; You M; Pikalov A; Tran QV
J Med Econ; 2009 Jun; 12(2):104-13. PubMed ID: 19527195
[TBL] [Abstract][Full Text] [Related]
37. Maintenance of response with atypical antipsychotics in the treatment of schizophrenia: a post-hoc analysis of 5 double-blind, randomized clinical trials.
Stauffer V; Ascher-Svanum H; Liu L; Ball T; Conley R
BMC Psychiatry; 2009 Mar; 9():13. PubMed ID: 19335905
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of atypical antipsychotic drugs (quetiapine, risperidone, aripiprazole and paliperidone) compared with placebo or typical antipsychotic drugs for treating refractory schizophrenia: overview of systematic reviews.
Melnik T; Soares BG; Puga ME; Atallah AN
Sao Paulo Med J; 2010 May; 128(3):141-66. PubMed ID: 20963366
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis.
Maher AR; Maglione M; Bagley S; Suttorp M; Hu JH; Ewing B; Wang Z; Timmer M; Sultzer D; Shekelle PG
JAMA; 2011 Sep; 306(12):1359-69. PubMed ID: 21954480
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]